Printer Friendly

MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.

Byline: Zacks Small Cap Research

By Ian Gilson, PhD, CFA

NASDAQ:MBII

READ THE FULL MBII RESEARCH REPORT

Marrone Bio Innovations (NASDAQ: MBII) has increased its line of credit based on accounts receivable from $7 million to $20 million and has added a line of credit backed by its inventory. Both additional funds will be made available from LSQ Funding Group [ https://lsq.com].

Small high growth companies frequently our pace their cash as they try to balance cash/accounts receivable/inventories/accounts payable with operating expenses. This is especially difficult when revenue is highly seasonal and costs occur in different accounting periods than accounts receivable are paid.

Lending organizations have a lot more access to the financials than do analysts so it is encouraging that LSQ Funding has such confidence in Marrone Bio Innovations to guarantee access to $18 million of additional funding.

Our estimates do not include any data from the recent acquisitions since no current or historical data is available at this time. When the impact of the acquisitions becomes available we will adjust our forecasts accordingly.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.

COPYRIGHT 2020 Accretive Capital LLC dba Benzinga.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Zacks Small Cap Research
Publication:Benzinga.com
Date:Jan 10, 2020
Words:337
Previous Article:Lime Shutting Down In 12 Markets Over Profitability Concerns.
Next Article:Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters